Home » Therapeutic Antibody » Antibody Drug Reagent Service » Pseudo Virus Neutralization Assay for SARS-CoV-2

Pseudo Virus Neutralization Assay for SARS-CoV-2

Entry of Coronavirus into host cells is mediated by the trimeric transmembrane spike (S) glycoprotein(fig1). S glycoprotein is surface-exposed and mediates entry into the host cells by binding to human angiotensin-converting enzyme 2 (ACE2), the SARS-CoV-2 receptor, which makes S glycoprotein the major target of neutralizing antibodies and the focus of therapeutic and vaccine design.

A model that simulates the infection of the SARS-CoV-2 is designed by replacing the envelope glycoprotein in the lentivirus vector with the S protein. Neutralizing antibodies blocking S protein(Fig.2) and receptor binding could prevent the virus from infecting host cells. By detecting the luminescence of target cells, it is possible to screen or verify the activity of the neutralizing antibody.

  • Fig.1 Pseudovirus with S glycoprotein as the envelope protein

  • Fig.2 Neutralizing antibodies preventing the pseudovirus from entering host cells

Workflow of Neutralization Assay

Service Highlights

  • Fast delivery:
    2-4 weeks to get results *
  • * The timeline is for reference. The timeline will extend accordingly with increasing number of samples to test.
  • High specificity:
    Ability to specifically screening drugs blocking pseudovirus entry.
  • High sensitivity:
    S / N as high as about 50-100, activities of different candidates can be clearly distinguished.
  • Virus entry assay model:
    A viral entry model, consistent with the physiological entry mechanism.
  • The pseudovirus can effectively entry the target cell line

  • Positive antibodies can effectively inhibit pseudovirus entries

  • Hela/ACE2 clones

  • Best cell line and clones are used as target cells